- Joined
- Apr 16, 2004
- Messages
- 4,661
- Reaction score
- 5,080
I read a very interesting article in the Red Journal: http://www.redjournal.org/article/S0360-3016(14)00494-5/pdf
It discusses how RO utilization has risen tremendously and is unsustainable by CMS. Obviously 'bundled payments' are all the rage but the article thoughtfully goes through a few models in significant detail and their applicability to RO.
1. Single specialty capitation - if NCCN gives several, equivalent alternatives for a given stage of malignancy (e.g. brachy, IMRT, protons for early stage prostate cancer) then you choose the cheapest one because you receive a flat payment regardless of the expense on your end.
2. Multi-specialty capitation - as above but gives a larger, bundled payment to be divided up by surgeon, RO and MO.
3. Episodic payments - give an up-front, 'lump sum' payment for each treatment site by stage. This 'lump sum' includes consultation, simulation, treatment planning, treatment delivery and follow-up for 90 days. The money given to ROs is a weighted average. For instance reimbursement for Stage III NSCLC might be 60% 3DCRT + 40% IMRT.
The authors note that none is 'perfect' but advocate #3 as their preferred choice.
Very interesting read.
It discusses how RO utilization has risen tremendously and is unsustainable by CMS. Obviously 'bundled payments' are all the rage but the article thoughtfully goes through a few models in significant detail and their applicability to RO.
1. Single specialty capitation - if NCCN gives several, equivalent alternatives for a given stage of malignancy (e.g. brachy, IMRT, protons for early stage prostate cancer) then you choose the cheapest one because you receive a flat payment regardless of the expense on your end.
2. Multi-specialty capitation - as above but gives a larger, bundled payment to be divided up by surgeon, RO and MO.
3. Episodic payments - give an up-front, 'lump sum' payment for each treatment site by stage. This 'lump sum' includes consultation, simulation, treatment planning, treatment delivery and follow-up for 90 days. The money given to ROs is a weighted average. For instance reimbursement for Stage III NSCLC might be 60% 3DCRT + 40% IMRT.
The authors note that none is 'perfect' but advocate #3 as their preferred choice.
Very interesting read.